Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1- yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[ 1,2,4]triazin-3-yl]-{4-[2-(1-oxy- pyrrolidin-1-yl)-ethoxy]-phenyl}-amine)

Drug Metabolism and Disposition

Volumn 35, Issue 6, 2007, Pages 929-936

  Hu, Steven Xicheng ^a   Soll, Richard ^a   Yee, Shiyin ^a   Lohse, Daniel L ^a   Kousba, Ahmed ^a   Zeng, Binqi ^a   Yu, Xiyun ^a   McPherson, Andrew ^a   Renick, Joel ^a   Cao, Jianguo ^a   Tabak, Arek ^a   Hood, John ^a   Doukas, John ^a   Noronha, Glenn ^a   Martin, Michael ^a  

^a TargeGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[7 (2,6 DICHLOROPHENYL) 5 METHYL BENZO[1,2,4]TRIAZIN 3 YL] [4 (2 PYRROLIDIN 1 YL ETHOXY)PHENYL]AMINE; [7 (2,6 DICHLOROPHENYL) 5 METHYL BENZO[1,2,4]TRIAZIN 3 YL] [4 [2 (1 OXYPYRROLIDIN 1 YL)ETHOXY]PHENYL]AMINE; DRUG METABOLITE; PROTEIN KINASE LCK; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TG 100435; TG 100855; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; BIOTRANSFORMATION; DOGS; FEMALE; MALE; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; PROTEIN KINASE INHIBITORS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SRC-FAMILY KINASES; TRIAZINES;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 34249110756     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.014290     Document Type: Article

References (34)

1. Beckett AH (1971) Metabolic oxidation of aliphatic basic nitrogen atoms and their alpha-carbon atoms. Xenobiotica 1:365-383.
2. 5, γ-propylamine with rat liver microsomes. Biomed Mass Spectrom 1:329-331.
3. Bickel MH (1972) Liver metabolic reactions: tertiary amine N-dealkylation, tertiary amine N-oxidation, N-oxide reduction, and N-oxide N-dealkylation. I. Tricyclic tertiary amine drugs. Arch Biochem Biophys 148:54-62.
4. Bu HZ, Zhao P, Kang P, Pool WF, and Wu EY (2006) Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos 34:1798-1802.
5. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, and Beume R (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297:280-290.
6. Carmella SG, Borukhova A, Akerkar SA, and Hecht SS (1997) Analysis of human urine for pyridine-N-oxide metabolites of 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone, a tobacco-specific lung carcinogen Cancer. Epidemiol Biomarkers Prev 6:113-120.
7. Cashman JR (2005) Some distinctions between flavin-containing and cytochrome P450 monooxygenases. Biochem Biophys Res Commun 338:599-604.
8. Cashman JR and Zhang J (2006) Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 46:65-100.
9. Cerecetto H and González M (2001) N-oxides as hypoxia selective cytotoxins. Mini Rev Med Chem 1:219-231.
10. Cho AK (1988) Metabolic disposition of nitrogen functionalities. Prog Bas Clin Pharmacol 1:184-212.
11. Cho AK and Lindeke B (1988) Biotransformation of Organic Nitrogen Compounds. Karger, Basel.
12. Ebling WF and Jusko WJ (1986) The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: the reversible metabolism of methylprednisolone and methylprednisone in rabbits. J Pharmacokinet Biopharm 14:557-599.
13. Foster AB, Griggs LJ, Jarman M, Van Maanen JMS, and Schulten HR (1980) Metabolism of Tamoxifen by rat liver microsomes: formation of the N-oxide, a new metabolite. Biochem Pharmacol 29:1977-1979.
14. Grothusen A, Hardt J, Brautigam L, Lang D, and Bocker R (1996) A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monoxygenases in human liver microsomes. Arch Toxicol 71:64-71.
15. Krueger SK, Vandyke JE, Williams DE, and Hines RN (2006) The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines. Drug Metab Rev 38:139-147.
16. Kuo BS, Poole JC, Hwang KK, and Cheng H (1993) Pharmacokinetics and metabolic interconversion of intravenous 4-amino-5-chloro-2-[(methylsulfinyl) ethoxy]-N-[2-(diethylamino)ethyl] benzamide and its sulfide and sulfone metabolites in rats. J Pharm Sci 82:694-698.
17. Lang DH, Yeung CK, Peter RM, Ibarra C, Gasser R, Itagaki K, Philpot RM, and Rettie AE (1998) Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem Pharmacol 56:1005-1012.
18. Levitzki A and Mishani E (2006) Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 75:93-109.
19. Lutz MP, Silke Eßer IB, Flossmann-Kast BBM, Vogelmann R, Lührs H, Friess H, Büchler MW, and Adler G (1998) Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243:503-508.
20. Miwa GT and Walsh JS (1988) Cytochrome P450 in nitrogen metabolism. Pro Bas Clin Pharmacol 1:27-62.
21. Mountfield RJ, Kiehr B, and John BA (2000) Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator in the rat. Drug Metab Dispos 28:503-513.
22. Noronha G, Barrett K, Boccia A, Brodhag T, Cao J, Chow CP, Dneprovskaia E, Doukas J, Fine R, Gong X, et al. (2007) Discovery of [7-(2,6-dichlorophenyl)- 5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)phenyl] amine - a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. Bioorg Med Chem Lett 17:602-608.
23. Noronha G, Barrett K, Cao J, Dneprovskaia E, Fine R, Gong X, Gritzen C, Hood J, Kang X, Klebansky B, et al. (2006) Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg Med Chem Lett 16:5546-5550.
24. Parte P and Kupfer D (2005) Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 33:1446-1452.
25. Patterson LH (2002) Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 34:581-592.
26. Prueksaritanont T, Lu P, Gorham L, Sternfeld F, and Vyas KP (2000) Interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase in hepatic metabolism of L-775,606, a potent 5-HTID receptor agonist. Xenobiotica 30:47-59.
27. Ripp SL, Itagaki K, Philpot RM, and Elfarra AA (1999) Species and sex differences in expression of flavin-containing monooxygenase form 3 in liver and kidney microsomes. Drug Metab Dispos 27:46-52.
28. Rucker G, Neugebauer M, and Zhong D (1992) Study on the metabolism of racemic prolintane and its optically pure enantiomers. Xenobiotica 22:143-152.
29. Skálová L, Nobilis M, Szotáková B, Wsól V, Kubíček V, Baliharová V, and Kvasničková E (2000) Effect of substituents on microsomal reduction of benzo(c)fluorine N-oxides. Chem-Biol Interact 126:185-200.
30. Trevino JG, Summy JM, and Gallick GE (2006) Src inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem 6:681-687.
31. Uematsu T, Sato R, Vozeh S, Follath F, and Nakashima M (1989) Relative electrophysiological potencies of quinidine, 3-OH quinidine and quinidine-N-oxide in guinea pig heart. Arch Int Pharmacodyn Ther 297:29-38.
32. Wong YN, Quon CY, Holm KA, Burcham DL, Frey NL, Huang SM, and Lam GN (1996) Pharmacokinetics and metabolism of EXP921, a novel cognitive enhancer, in rats. Drug Metab Dispos 24:172-179.
33. Wu WN, Hills JF, Chang SY, and Ng KT (1988) Metabolism of bepridil in laboratory animals and humans. Drug Metab Dispos 16:69-77.
34. Wu WN, Pritchard JF, Ng KT, Hilis JF, Uetz JA, Yorgey KA, Mckown LA, and O'Neill PJ (1992) Disposition of bepridil in laboratory animals and man. Xenobiotica 22:153-169.